



Investor Report

Unleashing the potential

IPA overview, insight and answers

HUB of Biotherapeutic Intelligence™
May 2023 | NASDAQ:IPA

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies LTD. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Further information on risks and uncertainties may be found in the Company’s Management Discussion & Analysis which may be obtained from SEDAR at www.sedar.com and SEC at www.sec.gov.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



Welcome

Dear Investors,

Our latest Investor Report includes a comprehensive overview of IPA (ImmunoPrecise Antibodies).

We will explore transformative strategies and cutting-edge innovations. We bring you insights on the company's vision, market positioning, future prospects, and potential growth through a Q&A format. Join us as we uncover the story behind IPA and discover why it is poised to revolutionize the industry.




Q: What are ImmunoPrecise's
business and strengths?



ImmunoPrecise Antibodies Ltd. (IPA) is an AI-driven biopharmaceutical research and technology company that specializes in utilizing artificial intelligence to better understand complex biological data and accelerate the discovery and development of novel antibodies. IPA's bioplatfroms include Function-First B Cell Select® workflow and phage display technologies. By powerfully combining these innovative technologies with AI-driven analysis, IPA can significantly enhance the efficiency and accuracy of therapeutic antibody discovery.

Here's a look at IPA's business and its significant strengths:

- **Comprehensive Therapeutic Antibody Services:** IPA's core business revolves around providing comprehensive therapeutic antibody discovery and development services. These services range from antigen design and immunization, high-throughput screening, antibody characterization and optimization, to manufacturing readiness, providing a true one-stop solution for clients.
- **Deep Domain Expertise:** IPA's team comprises highly experienced scientists and researchers with deep domain knowledge in therapeutic antibody discovery. This expertise enables the company to deliver high-quality, reliable products and services to its clients.



- **Global Presence:** IPA's operations span North America and Europe, allowing the company to serve a global clientele and address diverse therapeutic antibody needs across different markets.
- **Innovation and Proprietary Technology:** IPA leverages its proprietary antibody discovery platforms to deliver highly specific and diversified therapeutic antibody libraries, showcasing its commitment to innovation.



One of IPA's significant strengths comes from its subsidiary, BioStrand®:

BioStrand is a bioinformatics company that has developed a revolutionary approach to genomics research and data interpretation. Its LENS^{ai}™ Integrated Intelligence platform, powered by patented HYFTs[®] technology is designed to identify patterns in genetic data, providing a unique perspective on DNA, RNA, and protein analysis. BioStrand's innovative technology enhances IPA's capabilities, allowing for more precise and effective therapeutic antibody discovery.

BioStrand's strengths include:

1. Innovative LENS^{ai} platform powered by HYFTs Technology:

Enables the identification of unique patterns in genetic data, enhancing the precision and effectiveness of genomics research.

2. Data Integration Capabilities: Allowing integration of different modalities of data, including sequence data, 3D representations, and unstructured scientific knowledge, solving the Information Integration Dilemma in biology. This integrated approach provides a more comprehensive understanding of biological functions and disease processes.

3. Increased Competitive Advantage: The integration of BioStrand's technology provides IPA a significant competitive advantage in the therapeutic antibody discovery market. It enhances IPA's service offering, making it more appealing to clients seeking comprehensive, innovative, and effective antibody discovery solutions.

4. Shared Knowledge and Expertise: The partnership allows both companies to leverage their respective areas of expertise, driving innovation and growth. IPA's deep knowledge in therapeutic antibody discovery complements BioStrand's genomics and bioinformatics expertise.

5. Greater Efficiency: The combination could lead to more efficient processes. With BioStrand's capabilities to process and understand complex biological data, the speed and effectiveness of drug discovery and development can be improved, potentially reducing the time and cost associated with bringing new therapeutics to market.

In essence, the combination of IPA and BioStrand can potentially accelerate the discovery, development, and commercialization of novel biologics, benefiting patients, healthcare providers, and investors alike.

Q: What differentiates LENS^{ai},
powered by HYFTs, from other
competitive technologies in
AI and healthcare?



There are several key factors that differentiate BioStrand's LENS^{ai} Integrated Intelligence platform from other AI technologies in healthcare:

LENS^{ai} powered by HYFT Technology

1. Integration of Multiple Data Modalities into a single framework: HYFTs technology stands out in its ability to integrate different types of biological data, including sequence data, 3D structural information, and unstructured scientific knowledge. This allows for a more comprehensive understanding of biological functions and disease processes.

2. Unique Pattern Recognition: The HYFTs are unique identifiers found in DNA, RNA, and proteins. These represent functionally relevant biological patterns, thus providing a more meaningful interpretation of biological data than traditional sequence alignment methods.

3. Scalability: HYFTs technology allows for the analysis of large amounts of data, which is critical given the vast quantities of biological data available. This scalability is essential for high-throughput drug discovery and development.

4. Versatility: HYFTs technology is not limited to a specific disease or type of drug. It can be applied across different fields of research and various stages of drug development, making it a versatile tool in healthcare.

5. Structure-Function Relationships: By integrating 3D structural data, this technology can provide insights into how the structure of a molecule relates to its function. Understanding this relationship is crucial in drug design and understanding disease mechanisms.

Overall, BioStrand's HYFT technology provides a unique and powerful approach to understanding and interpreting biological data. Its ability to integrate and make sense of complex data sets can accelerate research and development, potentially leading to breakthroughs in healthcare.



Q: Can you please explain BioStrand's LENS^{ai} and HYFT Technology as simply as possible, so that an average layperson can understand what they are and how they could lead to major medical breakthroughs?



LENS^{ai} Integrated Intelligence Technology is a next-level artificial intelligence platform that is powered by advanced HYFT technology.

The platform is what is used to access real-time insights to allow analysis of complex data effortlessly. With LENS^{ai}, scientists can instantly access complex biological information, gain a deeper understanding of antibody-related research, collaborate with team members efficiently, and make timely and informed decisions, leading to potentially life-changing breakthroughs in healthcare at a rapid pace.

HYFT is a patented technology that powers LENS^{ai}. It is a bit like a highly sophisticated pattern recognition system.

Imagine if you had to read through a book written in a language you don't understand, and you were trying to find specific patterns of words or letters, even though you don't know what they mean. That's similar to what scientists are doing when they analyze genetic data.

Genetic data is composed of sequences of four different types of molecules — abbreviated as A, C, G, and T — and these sequences can be extremely long, with millions or even billions of these molecules. Understanding these sequences is crucial for discovering new drugs and diagnosing diseases, but the sheer amount of data makes it incredibly difficult.

This is where BioStrand's HYFTs come in. HYFTs are unique patterns in these genetic sequences that BioStrand's technology can identify. It's as if you suddenly had a tool that could instantly highlight all the important patterns in that book written in a language you don't understand.

The reason why this could lead to major medical breakthroughs is that these HYFTs are not just random patterns; they are associated with specific biological functions. By identifying these patterns, researchers can better understand how different sequences of genetic data can influence the way our bodies work, leading to the discovery of new drugs, better understanding of diseases, and even potential cures.

The power of BioStrand's HYFT technology is its ability to turn the complex language of genetic data into a pattern that can be more easily understood and interpreted, thereby speeding up research and medical advancements.



Q: How can HYFT technology be incorporated into Large Language Models (LLMs) to benefit pharmaceutical and biotech companies?



Incorporating BioStrand's HYFT technology into Large Language Models (LLMs) can greatly benefit pharmaceutical and biotech companies in a number of ways:

- 1. Improved Data Analysis:** HYFT technology's unique pattern recognition can be used to analyze the massive amounts of unstructured text data in the form of medical literature, research papers, clinical trial results, and more. LLMs equipped with HYFT technology can effectively understand and extract valuable insights from these data, making the research and development process more efficient.
- 2. Enhanced Drug Discovery:** By integrating HYFT technology into LLMs, companies can predict the structure-function relationships of potential drug targets and candidates more accurately. This can accelerate the drug discovery process and increase the likelihood of successful drug development.
- 3. Personalized Medicine:** HYFT technology can help LLMs to better understand individual genetic information, which can be used to develop personalized treatment plans. This has significant implications for precision medicine, a key focus area for many pharmaceutical and biotech companies.

4. Risk Mitigation: By providing a more comprehensive and accurate analysis of biological data, HYFT technology can help companies identify potential risks or adverse effects earlier in the drug development process, thereby reducing costs and time spent on unsuccessful paths.

5. Knowledge Integration: HYFT technology can connect disparate sources of data, creating a comprehensive knowledge graph. This graph, processed and understood by an LLM, can reveal new associations and hypotheses, driving innovative drug discovery and development.

Incorporating BioStrand's HYFT technology into LLMs ultimately enhances the models' ability to process and understand complex biological data. This integration provides a powerful tool for pharmaceutical and biotech companies, accelerating research and development, and potentially leading to major medical breakthroughs.



Q: How significant is the issuance of the patent for HYFT Technology by the European Patent Office (EPO)?



The issuance of the patent for HYFT technology by the European Patent Office (EPO) is highly significant for several reasons:

1. Validation: The patent approval validates the uniqueness and novelty of the HYFT Technology. It is a recognition that BioStrand's approach to pattern recognition and data analysis in the field of bioinformatics represents a genuine (and not obvious) innovation.

2. Protection: The patent provides legal protection for BioStrand's HYFT technology. This means that BioStrand has the exclusive right to use and commercialize their technology, protecting them from potential competitors.

3. Market Positioning: The patent also strengthens BioStrand's position in the market. It not only distinguishes them from other players in the industry, but also signals to potential partners and investors the unique value proposition and technological edge that BioStrand offers.

4. Opportunity for Expansion: With patent protection, BioStrand is better positioned to expand its operations. It also sets a precedent that may aid in obtaining patent protection in other jurisdictions, facilitating global expansion.

5. Investor Confidence: A granted patent can also increase investor confidence in BioStrand. It is often seen as a mark of technological competence and can make the company more attractive to potential investors.

Overall, the issuance of the patent for HYFT technology by the EPO is a significant milestone for BioStrand, further establishing the company's reputation as an innovator in the field of bioinformatics and AI-driven data analysis.



Q: What are wet lab experiments?



"Wet lab" experiments refer to experiments that are conducted in a laboratory setting using liquids and biological matter. This term is often used in biology, chemistry, and similar scientific disciplines to differentiate from "dry lab" experiments, which are more computational or theoretical in nature.

Wet labs are called such because of the nature of the work involved, often dealing with liquid solutions, reagents, or biological samples. They require specific infrastructure, like safety hoods, biocontainment levels, and specialized storage for biological samples and chemicals. They also require stringent safety measures due to the potential risks associated with handling biological or chemical materials.

These experiments are crucial for a variety of scientific fields, including medicine, microbiology, virology, biochemistry, and genetics, among others, as they allow for the practical application and testing of theories and hypotheses.



Q: What does
"in silico" mean?



***"In silico"* is a term used in biology that refers to experiments or processes that are carried out by computer modeling or computer simulation. The term is derived from the Latin phrase "in silice," which means "in silicon," referencing the silicon used in computer chips.**

This term is used in contrast with "*in vivo*" (experiments done in living organisms) and "*in vitro*" (experiments done outside of living organisms, typically in a lab setting like in a test tube or petri dish).

In silico experiments have become increasingly prevalent and important in many areas of biological and medical research. They can help researchers understand complex biological systems, predict how drugs will behave before they're tested in actual biological systems (thereby potentially saving time and resources), and explore hypotheses that might be impractical or unethical to test in a living system.

In the context of BioStrand's work, "*in silico*" refers to the computational modeling and analysis that the company's technology performs on biological and genomic data.



Q: Why are wet lab
experiments important
when evaluating
AI generated *in silico*
models?



Wet lab experiments are crucial in validating the predictions made by AI-generated *in silico* models for several reasons:

1. Ground Truth: Wet lab experiments provide empirical data, or "ground truth," against which the results of *in silico* models can be compared. This can help researchers understand the accuracy of their models and refine them for better predictions.

2. Complexity of Biological Systems: Biological systems are incredibly complex, with many interacting variables that can be difficult to account for in a computer model. Wet lab experiments allow researchers to observe how these variables interact in reality.

3. Unexpected Results: Wet lab experiments can often yield unexpected results that were not predicted by *in silico* models. These unexpected results can lead to new hypotheses and insights, improving our understanding of the biological systems in question.

4. Ethical and Regulatory Requirements: For medical interventions, such as drugs or therapies, regulatory authorities require extensive wet lab (and later, clinical) testing to ensure the safety and efficacy of the intervention. AI-generated models can accelerate this process by making more targeted predictions, but they can't replace it.

So, while *in silico* models, particularly those developed using AI, can greatly accelerate the process of discovery and development in biology and medicine, they still need to be complemented by traditional wet lab experiments to ensure their accuracy and reliability.



Q: Please provide a full bio for Dr. Dirk Van Hyfte

(Co-founder of BioStrand & HYFT technology)
and how his education and various career
experiences allowed him to crack the
code of the biosphere and develop the
HYFT Technology?



Dr. Dirk Van Hyfte, Co-founder of BioStrand and the mastermind behind HYFT technology, has charted an impressive career that combines expertise in medical informatics, artificial intelligence, clinical psychiatry, and enterprise software. His unique academic background and diverse career experiences have equipped him with the knowledge and skills to decode the complexities of the biosphere and pioneer the ground-breaking HYFT Technology.

Wanting to expand his knowledge into different fields to achieve a systems view of problem solving, Dirk pursued a Ph.D. in Medical Artificial Intelligence from Radboud University in 2000. This was a seminal period for Dirk, as it was during his Ph.D. that he started considering how to describe dynamic systems like brainwave patterns in psychiatric disorders using computational models.

In 1999, Dirk co-founded iKnow and served as the Co-Founder and Bio-Medical Advisor. iKnow was a significant success, providing unique text analytic technology for both structured and unstructured data, which was later acquired by InterSystems in 2010 to advance their AI capabilities.

His subsequent role as a consultant for Text Analytics and Biomedical Informatics, starting in 2011, further bolstered Dirk's expertise in AI and data analytics.

In 2019, Dirk co-founded BioStrand, BioKey, and BioClue. As co-founder and Chief Technology Officer (CTO) at BioStrand, Dirk led the company's technical strategy, transforming complex concepts into commercially viable solutions and aligning technological resources with business needs. Moreover, he held patents for a revolutionary algorithm for genomic data analysis as co-founder and technical mastermind at BioClue.



Dr. Dirk Van Hyfte (Co-founder of BioStrand & HYFT Technology)

Dirk's enduring quest to reveal the underlying connections between the universe and the biosphere led him to the discovery of the HYFTs, a breakthrough technology at BioStrand that simplifies the analysis and understanding of complex biological data. HYFTs are Universal Fingerprint™ patterns that can be mined from various sources across the biosphere. These patterns, when connected, form a comprehensive Knowledge Graph that provides a powerful resource for researchers in various biology fields.

Dirk's vision for HYFTs embodies a core principle from his early interest in astrobiology – the idea of ***finding recurring patterns or commonalities that could explain phenomena across the universe and the biosphere***. This innovative approach showcases Dirk's ability to merge his diverse expertise in psychiatry, medical artificial intelligence, and business to revolutionize the way we understand and interact with complex biological data.

Dr. Dirk Van Hyfte's accomplishments do not end with his professional milestones. He is a co-inventor of five patents, three of which are in the domain of biological sequence handling, and a co-author of several scientific publications within the fields of psychopharmacology, clinical psychiatry, medical AI, and natural language processing. All these accomplishments exemplify Dirk's unwavering dedication to innovation and his ability to push the boundaries of what is technologically possible.

Dirk's story is a testament to the power of interdisciplinary study and the quest for knowledge, demonstrating how curiosity and passion can lead to groundbreaking innovations that have the potential to revolutionize entire industries. His journey continues as he pushes forward in his mission to simplify and democratize access to complex biological data, making it more accessible and efficient for researchers and organizations worldwide.



Q: Why is the integration
of 20 million structural
HYFTs important?



In the context of BioStrand's pioneering work, the significance of integrating 20 million structural HYFTs is quite substantial:

1. Bridging Sequence to Structure: HYFTs provide a powerful link between sequence data and biological structure. The ability to connect Sequence HYFTs with Structural HYFTs is a game-changer. It allows for a more comprehensive understanding of how changes in DNA or protein sequences can impact the overall structure and function of a molecule, and consequently, the biological processes it is involved in.

2. Enhanced Query Capabilities: With 20 million structural HYFTs, a massive scope of biological data is covered. This allows researchers to formulate complex and specific queries, enabling intricate investigations and analyses of biological systems.

3. Simplifying Complex Data: By capturing the essence of biological data into HYFTs, the complexity of biological systems is greatly reduced. This allows for more streamlined data analysis and interpretation.

4. Facilitating Cross-Disciplinary Research: Since HYFTs serve as a kind of "universal language" in biological data, they can be used across different fields. This means that the insights derived from these 20 million structural HYFTs could benefit a wide range of scientific disciplines, from genomics and proteomics to drug discovery and precision medicine.

5. Empowering AI and Machine Learning Applications: The more data that machine learning algorithms can learn from, the better they can predict and generate insights. The integration of 20 million structural HYFTs provides a rich dataset for AI systems, leading to improved results and innovations.

6. Advancing Precision Medicine: With a broader range of HYFTs, it becomes possible to make more precise correlations between genomic data and disease states or treatment responses. This is a key advancement towards the full potential of precision medicine, where treatments are tailored to the unique genetic makeup of individual patients.



Q: Why are HYFTs being linked
to 25 billion relationships
within the Knowledge
Graph(KG) important?



Linking HYFTs to 25 billion relationships within the Knowledge Graph (KG) is incredibly significant for various reasons. This vast, interconnected network of biological data is a game-changer in life science research and applications. Here's why:

1. Rich Contextual Information: The KG is not just a collection of biological entities. Each relationship represents a valuable connection, a piece of the complex puzzle that are biological systems. With billions of these relationships, we can glean deep contextual insights into each HYFT, greatly enriching our understanding of their functions and interactions within biological systems.

2. Real-time Scientific Knowledge Integration: Unlike static databases, the KG integrates not only structured biological data but also unstructured information from scientific text. This includes the latest research findings, theories, and hypotheses from scientific literature, which are continually updated. This feature ensures that the knowledge graph and, by extension, the HYFTs remain current and relevant, reflecting the most recent advances in biological research.

3. Accelerated Research: With this extensive interconnected network of data, researchers can swiftly navigate and analyze intricate biological information. This accelerates research tasks, from identifying disease biomarkers to predicting protein functions and uncovering potential drug targets.

4. Improved Predictive Power: The machine learning adage "the more data, the better" holds true here. Training AI models on a KG filled with billions of relationships can enhance the accuracy of predictions, leading to more reliable insights and outcomes.

5. Holistic Data Integration: The KG serves as a unified framework where various types of biological data (e.g., genomics, proteomics, metabolomics) are integrated seamlessly. This holistic view of biological systems leads to more comprehensive insights and discoveries that might be missed when analyzing these data types separately.

6. Unique Feature: This fully integrated framework, combining structured and unstructured data into a continually updated KG, is a unique feature of the HYFT technology. This sets it apart from other technologies and elevates its capabilities in biological research and drug discovery.

The integration of HYFTs with billions of relationships in the KG profoundly enhances the potential of the HYFT technology. This integration creates a powerful tool for biological research and drug discovery, offering unique capabilities for generating up-to-date, comprehensive, and context-rich insights.



Q: What are BioStrand's
plans to commercialize
/monetize the HYFT
Technology?



Strategies BioStrand may adopt:

1. Licensing HYFT Technology: BioStrand can license HYFT technology to biotech companies, pharmaceutical firms, and research institutions. It can offer tiered licensing agreements based on the size of the organization and its intended use.

2. Developing Software-as-a-Service (SaaS) Platforms: The company could develop and commercialize platforms that utilize HYFT technology to analyze and interpret genomic and proteomic data. These platforms can be subscription-based, with different plans catering to various user needs.

3. Partnerships with Pharma and Biotech Companies: BioStrand could enter strategic partnerships with pharmaceutical and biotech companies. Through these partnerships, companies can leverage HYFT technology to accelerate drug discovery and development, enhance personalized medicine strategies, and more.

4. Collaborations with Academic and Research Institutions: The company could collaborate with universities and research institutions, providing them access to HYFT technology for their research. This could speed up scientific discoveries and lead to co-publications, enhancing BioStrand's reputation in the scientific community.

5. Consulting Services: BioStrand could offer consulting services, helping other organizations interpret and apply their data using HYFT technology.

6. Custom Solutions: BioStrand could provide custom solutions to organizations with unique needs, offering specialized applications of HYFT technology tailored to specific projects or challenges.



IpA

Q: How can HYFTs help
create biosimilars/biobetters?
What does this potentially
mean for the company?



A crucial point in the context of biosimilars and biobetters development.

The proprietary HYFTs technology developed by BioStrand offers a unique and powerful approach to designing and optimizing these biologic therapeutics. A standout feature of HYFTs is their ability to identify structure-function relationships that are similar, but derived from sequences that are different from the original patented biologic drug. This is significant as it opens possibilities for designing biosimilars and biobetters that are not only patent-free, but also potentially offer improved performance characteristics.

The ability to navigate around existing patents while maintaining or enhancing therapeutic efficacy could revolutionize the development of biosimilars and biobetters. It would provide a means to accelerate the entry of these drugs into the market, thus promoting competition, improving patient access to essential therapies, and potentially reducing healthcare costs.

From a company standpoint, the ability to design patent-free biosimilars and biobetters using HYFTs technology positions BioStrand favorably in the competitive biopharmaceutical landscape. It could attract strategic partnerships with pharmaceutical companies keen on leveraging this technology for their drug development programs, leading to increased revenue streams and growth opportunities for BioStrand.



IpA

Q: How are the HYFTs helping
with biomarker discovery?



Biomarker discovery is a critical aspect of medical research and drug development. Biomarkers are biological indicators that can help diagnose diseases, predict disease progression, and monitor the effectiveness of treatments.

HYFTs can play a significant role in biomarker discovery in several ways:

- 1. Data Integration:** Biomarker discovery often requires the integration of vast amounts of complex biological data, including genomic, proteomic, metabolomic, and transcriptomic data. HYFTs can be used to effectively organize and integrate this data, making it easier to identify potential biomarkers.
- 2. Pattern Recognition:** HYFTs are designed to recognize patterns within biological data. This is especially useful in biomarker discovery, as potential biomarkers often manifest as patterns within genomic, proteomic, or other types of data.
- 3. Speed and Efficiency:** HYFT technology can process and analyze large volumes of data quickly and efficiently. This can significantly accelerate the process of biomarker discovery, which traditionally involves manually sifting through massive amounts of data.

4. Predictive Analysis: Once potential biomarkers have been identified, HYFT technology can be used to predict their potential impact on disease progression or treatment effectiveness. This can help researchers determine which biomarkers are most promising and worthy of further investigation.

5. Disease Modeling: HYFTs can be used to create comprehensive disease models that incorporate potential biomarkers. These models can provide valuable insights into the underlying mechanisms of disease and guide the development of new treatments.

HYFT technology can facilitate biomarker discovery by integrating and analyzing vast amounts of complex biological data, identifying patterns that could indicate potential biomarkers, speeding up the discovery process, and providing predictive analysis and disease modeling capabilities.



Q: What are G Protein-Coupled Receptors (GPCRs)?



G Protein-Coupled Receptors (GPCRs) are a large and diverse family of proteins that sit in the cell membrane and are found throughout the body. They play a crucial role in numerous biological functions and are the targets of a significant number of modern medicinal drugs.

The term "G protein-coupled" comes from these receptors' ability to interact with G proteins (guanine nucleotide-binding proteins) within the cell. When a specific molecule or signal, known as a ligand, binds to a GPCR on the outside of the cell, it triggers a conformational change in the receptor. This change activates the G protein inside the cell, initiating a cascade of further signaling events. These intracellular signals can influence many cellular processes, such as gene transcription, cell growth, or neuronal transmission.

GPCRs can respond to a diverse array of signals, including light, odors, hormones, neurotransmitters, and even certain types of cells. Due to their involvement in many critical biological processes, any dysfunction or alteration in GPCR signaling pathways can lead to a variety of diseases, including diabetes, depression, asthma, and hypertension, among others. Consequently, GPCRs are a significant focus in the field of drug discovery and development.



GPCRs are like tiny "switchboards" found on the surface of cells in our body. These switchboards help cells understand what's happening in their environment by receiving signals in the form of light, smells, hormones, or even neurotransmitters, which are the brain's chemical messengers.

Here's how they work: When a specific signal, such as a hormone, reaches the cell, it latches onto the GPCR, much like a key fitting into a lock. This action flips the switch and triggers the G protein inside the cell, which then sets off a series of events like a domino effect. This chain reaction can influence various processes within the cell, leading to changes in things like our heart rate, sense of smell, or mood.

Given their crucial role in so many body functions, it's not surprising that problems with GPCRs can lead to a variety of health issues, including asthma, diabetes, and depression. For this reason, many medications aim to target these receptors to help treat these conditions.

The HYFT Technology developed by BioStrand has the potential to revolutionize our understanding and manipulation of GPCRs, thus opening new avenues for improving human health.



Q: How will HYFT technology help in the advancement of GPCRs to improve human health?



GPCRs play a crucial role in the body's cellular communication. However, despite their importance, our understanding of these receptors, their structures, and the various ways they interact with different molecules, is still limited. This gap in knowledge often hampers the development of more effective, targeted therapies.

The HYFT technology can help overcome these limitations by capturing and analyzing the complex patterns and relationships in biological data, including those involving GPCRs. This technology can identify Universal Fingerprint™ patterns or HYFTs, which are the recurring patterns that can be found in various sources across the biosphere. The identified HYFTs are then connected to form a comprehensive Knowledge Graph, which encompasses millions of HYFTs and billions of relationships.

When applied to GPCRs, HYFT Technology can help uncover new insights about these receptors. For instance, it can help identify previously unknown relationships between different GPCRs, or between GPCRs and various molecules. Such insights could lead to the discovery of new drug targets or the development of more effective drugs.

Moreover, by linking sequences to structures and functions, HYFTs can help researchers better understand the structure-function relationships of GPCRs. Such understanding is crucial for designing drugs that can precisely target specific GPCRs, leading to more effective treatments with fewer side effects.

The HYFT technology also allows for the continuous enrichment and updating of the Knowledge Graph with the latest information. This feature ensures that researchers working on GPCRs always have access to the most current and comprehensive knowledge base, facilitating their research and drug development efforts.

In essence, HYFT technology empowers researchers with a powerful and dynamic tool for understanding and manipulating GPCRs, thereby paving the way.



Q: How can HYFT technology
help agriculture companies?



HYFT technology can be a game-changer for agriculture companies, offering a multitude of benefits in crop improvement, disease resistance, and environmental sustainability.

Here's how:

- 1. Crop Improvement:** By identifying specific HYFTs associated with desirable traits (like high yield, nutrient content, or drought tolerance), breeders can select for these traits more efficiently. This could lead to the development of superior crop varieties in a shorter time frame.
- 2. Disease and Pest Resistance:** HYFT technology can help identify genes and pathways associated with disease and pest resistance. This information can be used to develop crops that are naturally resistant to specific pests or diseases, reducing the reliance on chemical pesticides and fungicides.
- 3. Environmental Sustainability:** By identifying HYFTs associated with traits like nitrogen use efficiency or drought tolerance, we can develop crops that require fewer inputs or that can thrive in challenging environmental conditions. This can contribute to more sustainable agricultural practices.

4. Accelerated Research: The massive amount of data available in agriculture can be overwhelming. HYFT technology can help integrate and make sense of this data, accelerating research and development efforts.

5. Predictive Analytics: With HYFT technology, agriculture companies can predict the effect of certain genomic modifications. This can help guide breeding or genetic engineering efforts.

6. Data Integration: HYFTs can integrate various forms of data - genomic, phenotypic, environmental, and more. This can offer a holistic view of the plant and its interactions with the environment, aiding in more comprehensive and accurate decision-making.

In essence, HYFT technology can help agriculture companies develop more resilient, sustainable, and productive crops, while accelerating research efforts and aiding in effective decision-making.

Q: How Can HYFT technology
help cellular agriculture
companies?



IpA



Cellular agriculture is an innovative field that aims to produce agricultural products from cell cultures rather than from whole plants or animals. Here, HYFT technology can be instrumental in various ways:

1. Optimizing Cell Lines: HYFT technology can be used to analyze the genetic profiles of different cell lines. By connecting these profiles to known genetic markers and traits, companies can optimize their cell lines for maximum productivity, efficiency, or other desirable characteristics.

2. Enhancing Nutritional Profiles: HYFTs can be used to identify genetic markers associated with the production of certain nutrients within cells. This can help companies engineer cells to produce meat or dairy substitutes with enhanced nutritional profiles.

3. Improving Scalability: Cellular agriculture often faces the challenge of scaling up production while maintaining product quality and consistency. By identifying key genetic markers and pathways associated with growth and differentiation, HYFT technology can help companies improve the scalability of their production processes.

4. Accelerating R&D: By connecting various data types (genomic, proteomic, metabolomic, etc.), HYFTs can accelerate the research and development process in cellular agriculture, speeding up the discovery of efficient cell lines, growing conditions, or production processes.

5. Predictive Analysis: HYFT technology's ability to model complex genetic interactions can help in predictive analysis. For instance, it can predict how a change in a cell line's genetics might impact its growth rate, nutritional profile, or other properties.

6. Regulation and Safety: HYFT technology can assist in regulatory and safety evaluations by providing a thorough genetic analysis of cell lines, helping to identify any potential safety concerns and ensuring the end products are safe for consumption.

In essence, HYFT technology can assist cellular agriculture companies by optimizing their production processes, enhancing the nutritional value of their products, and speeding up their research and development efforts, among other benefits.



Q: How can HYFT technology specifically help a company such as Cargill, for instance?



HYFT Technology specific to Cargill:

1. Sustainable Agriculture: HYFT technology can serve as a revolutionary tool for crop improvement. It allows for the identification of HYFTs associated with critical traits such as drought resistance, disease resistance, or increased yield. Using this information, Cargill could develop or breed crop varieties possessing these beneficial traits, leading to more sustainable and resilient agricultural practices. The technology could also be used to monitor the health and status of crops, identifying potential issues before they become major problems.


2. Animal Nutrition and Health: With HYFT technology, Cargill can better understand the genetics behind animal growth, health, and nutrition. This includes identifying HYFTs that correlate with better absorption of nutrients, resistance to specific diseases, or enhanced growth rates. These insights could lead to the development of advanced, genetically-optimized feeds, resulting in healthier livestock and improved productivity for farmers.

3. Food Innovation: HYFT technology's ability to elucidate the complex relationships between genetic composition, structure, and function in biological systems can be instrumental in food innovation. Cargill could leverage these insights to create new food products or improve the nutritional content, taste, and texture of existing ones. The tech could also aid in identifying allergenic proteins and finding non-allergenic substitutes, leading to safer food products.

4. Biotechnology Advancements: Biotechnology is a significant part of modern agriculture, and Cargill stands at the forefront of this field. HYFT technology can accelerate the discovery and development of novel biotech solutions. For instance, it could help identify new enzymes for more efficient food processing or biofuel production. It could also aid in the discovery of novel probiotics to enhance gut health in humans and animals, thereby improving overall health and wellbeing.

5. Supply Chain Transparency: Authenticity and quality assurance are paramount in today's food supply chains. By decoding the genetic profiles of crops, HYFT technology can ensure the genuineness of sourced products, providing an extra layer of trust and transparency for Cargill's customers. For instance, it could differentiate organically grown crops from conventionally grown ones or identify the origin of specific crop varieties.

By integrating HYFT technology into their business model, Cargill could not only innovate and optimize their products and services but also fortify their commitment to sustainable and responsible practices.



Join the revolution

The potential of IPA presents a compelling opportunity for investors.

With its patented cutting-edge AI technology, #1 globally ranked contract research¹, strong intellectual property portfolio, and innovative therapies and manufacturing, the company is poised to make significant advancements in the field of biotechnology. The increasing demand for novel treatments, coupled with the company's talented minds, positions it well for success.

The HUB of Biotherapeutic Intelligence™
www.ipatherapeutics.com | NASDAQ:IPA

1. ROOTS 2022, Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; pp.118